Dana-Farber Cancer Institute | Strategic Alliance Partners

April 04, 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses immunotherapy plus chemotherapy in bladder cancer.

April 02, 2018

In an extended follow-up of results from the CheckMate-205 trial, nivolumab (Opdivo) induced an overall objective response rate of 69% in patients with relapsed/refractory classical Hodgkin lymphoma after autologous hematopoietic cell transplantation.

March 28, 2018

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses trials investigating combinations with immunotherapy for patients with bladder cancer.

March 27, 2018

Elizabeth A. Mittendorf, MD, PhD, Robert and Karen Hale Distinguished Chair in Surgical Oncology, director, Breast Immuno-Oncology Program, Director of Research, Breast Surgical Oncology, Dana-Farber/Brigham and Women’s Cancer Center, discusses immunotherapy efforts in breast cancer.

March 13, 2018

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses bone-targeted agents for patients with renal cell carcinoma (RCC).

March 10, 2018

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses approaches to treating lymphedema in patients with breast cancer.

March 03, 2018

Matthew S. Davids, MD, discusses the key results of ibrutinib (Imbruvica) with standard frontline chemoimmunotherapy in CLL.

February 27, 2018

Daniel J. DeAngelo, MD, PhD, medical oncologist, Dana-Farber Cancer Institute, discusses ongoing trials of patients with acute myeloid leukemia (AML).

February 21, 2018

Low-coverage genome-wide sequencing of cell-free DNA from plasma is capable of profiling cancer genomes from blood and predicting survival outcomes for patients with metastatic triple-negative breast cancer.

February 20, 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses a novel prognostic marker for patients with advanced bladder cancer being treated with the PD-L1 inhibitor atezolizumab (Tecentriq).

February 20, 2018

Guru Sonpavde, MD, discusses the importance of clinical trial enrollment for patients with penile cancer.

February 20, 2018

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses challenges with immunotherapy in bladder cancer.

February 14, 2018

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses axillary node dissection in patients with breast cancer.

February 13, 2018

Christopher Sweeney, MBBS, discusses the role of abiraterone for patients with hormone-sensitive prostate cancer, and what physicians should consider when choosing between abiraterone and docetaxel.

February 08, 2018

Jennifer A. Chan, MD, discusses the significance of the phase II results of cabozantinib in patients with carcinoid tumors and pancreatic NETs.

February 05, 2018

Matthew S. Davids, MD, MMSc, associate director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia, discusses results of a study combining ibrutinib (Imbruiva) plus fludarabine-cyclophosphamide-rituximab (FCR) in patients with chronic lymphoctic leukemia (CLL).

January 30, 2018

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses the role of sentinel lymph node biopsy in breast cancer.

January 11, 2018

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses tailoring treatment to individual patients with prostate cancer.

January 03, 2018

Guru Sonpavde, MD, director of Bladder Cancer at the Dana-Farber Cancer Institute, discusses the potential for immunotherapy in penile cancer.

December 16, 2017

Matthew S. Davids, MD, MMSc, Associate Director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia, discusses ibrutinib plus FCR in younger patients with CLL.